This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Edisbiotech Co., Ltd., The Asan Foundation, University of Ulsan Foundation for Industry Cooperation. Active years: 2025.
Company Filing History:
1 out of 1 
1 out of 84 
1 out of 94 
Years Active: 2025
Title: A-Neum Lee: Innovator in Monoclonal Antibody Development
Introduction
A-Neum Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His innovative work has the potential to enhance diagnostic accuracy in cancer detection.
Latest Patents
A-Neum Lee holds a patent for a monoclonal antibody specifically binding to CCSP-2 and its use. The patent describes a monoclonal antibody that targets the EGF2 domain of colon cancer secreted protein-2 (CCSP-2). This invention demonstrates significantly increased affinity and specificity compared to existing peptides and antibodies related to CCSP-2. The advancements made through this patent could lead to more accurate diagnoses by enabling specific detection of CCSP-2 at the protein level.
Career Highlights
Throughout his career, A-Neum Lee has worked with notable organizations, including the Asan Foundation and Edisbiotech Co., Ltd. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
A-Neum Lee has collaborated with talented individuals such as Hye-Nam Son and Hyori Kim. These partnerships have played a crucial role in advancing his research and innovations.
Conclusion
A-Neum Lee's contributions to monoclonal antibody development mark him as a significant figure in biotechnology. His work not only enhances our understanding of cancer diagnostics but also paves the way for future innovations in the field.